Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 4,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Completed Phase 3 Interventional Results available

Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea

NCT02498418
View directory record Official record
Conditions
Diarrhea
Interventions
Rifaximin, Xifaxan®, Placebo Tablet
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 20, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Test a New Drug to Treat Major Depression

NCT00976560
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
GW856553, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Hoffman Estates, Illinois • Park Ridge, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 20, 2026, 10:32 AM EDT
Completed Not applicable Interventional

Development and Piloting of a Just-in-Time, Personalized HIV Prevention Intervention for Youth Experiencing Homelessness and Unstable Housing

NCT03911024
View directory record Official record
Conditions
Behavior, Risk
Interventions
HIV, General health
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 20, 2026, 10:32 AM EDT
Completed Phase 3 Interventional Results available

The CLEVER Study - Coreg And Left Ventricular Mass Regression

NCT00108082
View directory record Official record
Conditions
Hypertrophy, Left Ventricular
Interventions
carvedilol MR, atenolol, lisinopril
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
78
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 20, 2026, 10:32 AM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

NCT01720524
View directory record Official record
Conditions
Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions
placebo, iv sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
0 Days to 4 Days
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
20
States / cities
Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 20, 2026, 10:32 AM EDT
Completed Phase 3 Interventional Results available

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

NCT01571362
View directory record Official record
Conditions
Chronic Pain, Low Back Pain, Analgesia
Interventions
ALO-02, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
52
States / cities
Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 20, 2026, 10:32 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

NCT06504446
View directory record Official record
Conditions
Refractory or Unexplained Chronic Cough
Interventions
NOC-110, Placebo
Drug · Other
Lead sponsor
Nocion Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
68
States / cities
Foley, Alabama • Scottsdale, Arizona • Tempe, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 20, 2026, 10:32 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

NCT04701983
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Itepekimab SAR440340, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
75
States / cities
Birmingham, Alabama • Jasper, Alabama • Chandler, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 10:32 AM EDT
Withdrawn Phase 2 Interventional

4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine

NCT03578354
View directory record Official record
Conditions
Vestibular Migraine, Migraine Disorders, Vestibular Diseases
Interventions
4-aminopyridine, Atenolol, Placebo
Drug · Other
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 20, 2026, 10:32 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

NCT06333808
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
51
States / cities
Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 20, 2026, 10:32 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Blood Sugar Take Care and Glucose Metabolism

NCT01554020
View directory record Official record
Conditions
Prediabetes
Interventions
Blood Sugar Take Care, Placebo
Dietary Supplement
Lead sponsor
NewChapter, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Oct 20, 2026, 10:32 AM EDT
Completed Phase 3 Interventional Results available

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

NCT04181723
View directory record Official record
Conditions
Rett Syndrome
Interventions
Trofinetide, Placebo
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 20 Years · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 20, 2026, 10:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout

NCT02139046
View directory record Official record
Conditions
Gout
Interventions
Febuxostat IR, Febuxostat XR, Febuxostat placebo, Colchicine, Naproxen, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
192
States / cities
Binghamton, Alabama • Birmingham, Alabama • Huntsville, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 20, 2026, 10:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dysphagia Following Anterior Cervical Spine Surgery; Single Dose Steroid vs Saline (DysDexVSSal)

NCT03711474
View directory record Official record
Conditions
Dysphagia
Interventions
Dexamethasone, Saline
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 20, 2026, 10:32 AM EDT
Completed Phase 2 Interventional

A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease

NCT01843790
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
GCS-100, Placebo, Saline
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Tempe, Arizona • La Mesa, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 20, 2026, 10:32 AM EDT
Withdrawn Phase 4 Interventional

Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil

NCT00625079
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Hypertension
Interventions
sildenafil
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 20, 2026, 10:32 AM EDT
Completed Phase 3 Interventional

A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome

NCT05358886
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
BPN14770/ zatolmilast, Placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Irvine, California • Orange, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 20, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis

NCT04523220
View directory record Official record
Conditions
End-stage Renal Disease, Prevention of Thromboembolic Events, Hemodialysis, Hemodiafiltration
Interventions
BAY1213790 (Osocimab), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
26
States / cities
Azusa, California • Brawley, California • Encino, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 20, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)

NCT00286182
View directory record Official record
Conditions
Anemia
Interventions
Erythropoietin alpha, Placebo
Drug
Lead sponsor
Mathew S. Maurer
Other
Eligibility
55 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 20, 2026, 10:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

NCT02708680
View directory record Official record
Conditions
Breast Cancer
Interventions
Entinostat, Atezolizumab, Placebo
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Bakersfield, California • Fullerton, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 20, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

Chlorthalidone in Chronic Kidney Disease

NCT02841280
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hypertension
Interventions
Chlorthalidone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 20, 2026, 10:32 AM EDT
Completed No phase listed Observational

The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings

NCT00830570
View directory record Official record
Conditions
Embolism and Thrombosis, Embolism, Vascular Diseases, Warfarin, Venous Thromboembolism, Thrombosis, Thromboembolism
Interventions
CYP 2C9 and VKORC1 Testing for Warfarin
Other
Lead sponsor
Medco Health Solutions, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
1,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Franklin Lakes, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2010 · Synced Oct 20, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression

NCT00376220
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Riluzole, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 20, 2026, 10:32 AM EDT
Recruiting Phase 2 Interventional

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

NCT07323654
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
KT-621, Placebo
Drug · Other
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
34
States / cities
Lancaster, California • Long Beach, California • Northridge, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 10:32 AM EDT